Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Candel Therapeutics (CADL) Non-Current Deffered Revenue (2020 - 2023)

Historic Non-Current Deffered Revenue for Candel Therapeutics (CADL) over the last 4 years, with Q3 2023 value amounting to $108000.0.

  • Candel Therapeutics' Non-Current Deffered Revenue changed N/A to $108000.0 in Q3 2023 from the same period last year, while for Sep 2023 it was $108000.0, marking a year-over-year change of. This contributed to the annual value of $144000.0 for FY2022, which is 8389.26% down from last year.
  • Candel Therapeutics' Non-Current Deffered Revenue amounted to $108000.0 in Q3 2023.
  • In the past 5 years, Candel Therapeutics' Non-Current Deffered Revenue registered a high of $894000.0 during Q4 2021, and its lowest value of $108000.0 during Q3 2023.
  • Moreover, its 4-year median value for Non-Current Deffered Revenue was $349000.0 (2021), whereas its average is $395625.0.
  • Its Non-Current Deffered Revenue has fluctuated over the past 5 years, first skyrocketed by 4145.57% in 2021, then crashed by 8389.26% in 2022.
  • Candel Therapeutics' Non-Current Deffered Revenue (Quarter) stood at $632000.0 in 2020, then skyrocketed by 41.46% to $894000.0 in 2021, then tumbled by 83.89% to $144000.0 in 2022, then dropped by 25.0% to $108000.0 in 2023.
  • Its Non-Current Deffered Revenue was $108000.0 in Q3 2023, compared to $120000.0 in Q2 2023 and $132000.0 in Q1 2023.